The year 2014 witnessed the approval by the US Food and Drug Administration (FDA) of 42 new molecular entities (NMEs), which is well above recent averages. These molecules targeted a range of molecular pathways and clinical indications, although the latter was skewed toward hepatitis C virus (HCV) infection and diabetes. By contrast, a single drug was approved for cardiovascular diseases and none for neurological indications (excepting sleeping disorders). Of note is a continued trend toward consolidation because the net number of biotechnology companies has reached its lowest point in over 25 years, raising questions about sustainability.

Original languageEnglish
Pages (from-to)620-624
Number of pages5
JournalDrug Discovery Today
Issue number4
StatePublished - Apr 1 2017


Dive into the research topics of '2014 in review: FDA approval of new drugs'. Together they form a unique fingerprint.

Cite this